Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Literature DB >> 8092845

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

P M Roblin¹, G Montalban, M R Hammerschlag.

Abstract

The in vitro susceptibilities of 12 strains of Chlamydia pneumonia to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chlamydiacidal concentration for 90% of strains tested of 0.5 micrograms/ml.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1994 PMID： 8092845 PMCID： PMC188218 DOI： 10.1128/AAC.38.6.1402

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors: M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal: Clin Infect Dis Date: 1992-01 Impact factor: 9.079

2. Infection with Chlamydia pneumoniae in Brooklyn.

Authors: K Chirgwin; P M Roblin; M Gelling; M R Hammerschlag; J Schachter
Journal: J Infect Dis Date: 1991-04 Impact factor: 5.226

3. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors: B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal: Am J Med Date: 1990-12 Impact factor: 4.965

Review 4. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors: J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal: J Infect Dis Date: 1990-04 Impact factor: 5.226

5. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors: M Kimura; T Kishimoto; Y Niki; R Soejima
Journal: Antimicrob Agents Chemother Date: 1993-04 Impact factor: 5.191

6. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

Authors: G E Kenny; F D Cartwright
Journal: Antimicrob Agents Chemother Date: 1993-08 Impact factor: 5.191

7. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.

Authors: R Wise; J M Andrews; N Brenwald
Journal: J Antimicrob Chemother Date: 1993-04 Impact factor: 5.790

8. In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors: M R Hammerschlag; C L Hyman; P M Roblin
Journal: Antimicrob Agents Chemother Date: 1992-03 Impact factor: 5.191

9. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors: T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal: Antimicrob Agents Chemother Date: 1992-03 Impact factor: 5.191

10. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors: K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1988-10 Impact factor: 5.191

10 in total

9 in total

1. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

Authors: P M Roblin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

2. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors: P M Roblin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1998-04 Impact factor: 5.191

3. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.

Authors: F Crokaert; M Aoun; V Duchateau; P Grenier; A Vandermies; J Klastersky
Journal: Eur J Clin Microbiol Infect Dis Date: 1996-08 Impact factor: 3.267

4. In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors: P M Roblin; A Kutlin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1997-09 Impact factor: 5.191

5. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.

Authors: R Soejima; Y Niki; T Kishomoto; M Kimura; Y Kubota
Journal: Drugs Date: 1995 Impact factor: 9.546

9. Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.

Authors: W M McCormack; D H Martin; E W Hook; R B Jones
Journal: Infect Dis Obstet Gynecol Date: 1998